New hope for Schizophrenia's most stubborn symptoms?
NCT ID NCT07565428
First seen May 05, 2026 · Last updated May 12, 2026 · Updated 2 times
Summary
This study tests a new drug called roluperidone for treating negative symptoms of schizophrenia, like lack of motivation and social withdrawal. About 380 adults with schizophrenia will take the drug or a placebo for 12 weeks to see if it improves these symptoms, then continue for 40 more weeks to check if it helps prevent relapse. The goal is to find a treatment that works better than current options for these hard-to-treat symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEGATIVE SYMPTOMS OF SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CBH Health, LLC dba CenExel
RECRUITINGGaithersburg, Maryland, 20877, United States
-
Hassman Research Institute, LLC dba CenExel
RECRUITINGMarlton, New Jersey, 08053, United States
Conditions
Explore the condition pages connected to this study.